Physiological relevance of hydrolysis of atrial natriuretic peptide by endothelin-converting enzyme-1

Kobe Journal of Medical Sciences

Volumn 58, Issue 1, 2012, Pages

  Nakayama, Kazuhiko ^a,b   Emoto, Noriaki ^a,b   Suzuki, Yoko ^b   Vignon Zellweger, Nicolas ^b   Yagi, Keiko ^b   Ken Ichi, Hirata ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atrial natriuretic peptide; Endothelin 1; Endothelin converting enzyme 1; Neutral endopeptidase 24.11

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COMPLEMENTARY DNA; ENDOTHELIN CONVERTING ENZYME; MESSENGER RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATRIAL NATRIURETIC PEPTIDE GENE; CELL ASSAY; CHO CELL; CONTROLLED STUDY; EMBRYO; ENDOTHELIN CONVERTING ENZYME GENE; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; GENE; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ATRIAL NATRIURETIC FACTOR; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; HYDROLYSIS; METALLOENDOPEPTIDASES; MICE; NEPRILYSIN;

EID: 84863539851     PISSN: 00232513     EISSN: 18830498     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ahn, K., Sisneros, A.M., Herman, S.B., Pan, S.M., Hupe, D., Lee, C., Nikam, S., Cheng, X.M., Doherty, A.M., Schroeder, R.L., Haleen, S. J., Kaw, S., Emoto, N., Yanagisawa, M. 1998. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 243: 184-190.
2. Baynash, A.G., Hosoda, K., Giaid, A., Richardson, J.A., Emoto, N., Hammer, R.E., and Yanagisawa, M. 1994. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79: 1277-1285.
3. Clouthier, D.E., Hosoda, K., Richardson, J.A., Williams, S.C., Yanagisawa, H., Kuwaki, T., Kumada, M., Hammer, R.E., and Yanagisawa, M. 1998. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125: 813-824.
4. Emoto, N., Raharjo, S.B., Isaka, D., Masuda, S., Adiarto, S., Jeng, A.Y., and Yokoyama, M. 2005. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45: 1145-1152.
5. Emoto, N., and Yanagisawa, M. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270: 15262-15268.
6. Hosoda, K., Hammer, R.E., Richardson, J.A., Baynash, A.G., Cheung, J.C., Giaid, A., and Yanagisawa, M. 1994. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267-1276.
7. Johnson, G.D., Stevenson, T., and Ahn, K. 1999. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 274: 4053-4058.
8. Kedzierski, R.M., and Yanagisawa, M. 2001. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876.
9. Kelland, N.F., and Webb, D.J. 2006. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) 231: 696-699.
10. Kirkby, N.S., Hadoke, P.W., Bagnall, A.J., and Webb, D.J. 2008. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119.
11. Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., Kuwaki, T., Cao, W.H., Kamada, N., Jishage, K., Ouchi, Y., Azuma, S., Toyoda, Y., Ishikawa, T., Kumada, M., Yazaki, Y. 1994. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368: 703-710.
12. Lee, C.Y., and Burnett, J.C., Jr. 2007. Natriuretic peptides and therapeutic applications. Heart Fail Rev 12: 131-142.
13. Miyagawa, K., Emoto, N., Widyantoro, B., Nakayama, K., Yagi, K., Rikitake, Y., Suzuki, T., and Hirata, K. 2010. Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. Hypertension 55: 738-746.
14. Omland, T., Lie, R.T., Aakvaag, A., Aarsland, T., and Dickstein, K. 1994. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89: 1573-1579.
15. Roques, B.P., Noble, F., Dauge, V., Fournie-Zaluski, M.C., and Beaumont, A. 1993. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146.
16. Spieker, L.E., Noll, G., Ruschitzka, F.T., and Luscher, T.F. 2001. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 37: 1493-1505.
17. Stewart, D.J., Cernacek, P., Costello, K.B., and Rouleau, J.L. 1992. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85: 510-517.
18. Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D., and Yanagisawa, M. 1994. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78: 473-485.
19. Yanagisawa, H., Hammer, R.E., Richardson, J.A., Emoto, N., Williams, S.C., Takeda, S., Clouthier, D.E., and Yanagisawa, M. 2000. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105: 1373-1382.
20. Yanagisawa, H., Yanagisawa, M., Kapur, R.P., Richardson, J.A., Williams, S.C., Clouthier, D.E., de Wit, D., Emoto, N., and Hammer, R.E. 1998. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125: 825-836.